Keyword: Congress

Think the entire pharma industry has moved past the old strategy of buying drug rights, jacking up prices and reaping the rewards? Think again.

Catalyst is unfazed by a letter from Sen. Bernie Sanders demanding that it justify the cost of its rare-disease drug Firdapse, confirmed at $300K after discounts.

UnitedHealthcare is making demands about pharma's new strategy to lower prices, an analyst wrote.

Reps. Frank Pallone Jr. and Diana DeGette sent letters to executives of insulin makers requesting answers about pricing.

Between President Trump on Twitter and critics in Congress, pharma and its pricing faced daily fire last year. But the industry's top lobbyists shot back.

The new Senate is once again sharpening its ax to cut pharma's DTC advertising tax deductions, a move now backed by a powerhouse group of Democrats.

Past pharma mergers have spawned price hikes, two U.S. representatives argue—and DTC and DOJ need to weigh the $74 billion deal with that in mind.

The Democrats' new drug pricing bills are "flawed"—and likely to fail—unless Trump crosses the aisle. And as one analyst sees it, he just might.

More than half of industry respondents in a GlobalData survey said pricing remains pharma's top concern in 2019.

After controversy and a price-hiking pause for some companies last year, several drugmakers are raising prices in early 2019.